WILD-TYPE Tp53 UNDERGOES A CELL TYPE-SPECIFIC INACTIVATION BY SIRT1 IN DE NOVO GLIOBLASTOMA

被引：0
|
作者：
Li, Li [1 ]
Vemireddy, Vamsidhara [1 ]
Goodarzi, Mohammad [1 ]
Mashimo, Tomoyuki [1 ]
Billman, Tara [1 ]
Hatanpaa, Kimmo [1 ]
Mickey, Bruce [1 ]
Maher, Elizabeth [1 ]
Bachoo, Robert [1 ]
Piccirillo, Sara [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
来源：
NEURO-ONCOLOGY | 2018年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GENE-03
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [41] Association of Wild-Type TP53 with Downregulation of Lovastatin Sensitivity in Human Non-Small Cell Lung Cancer Cells
    Chang, Yu-Yao
    Yang, Tsung-Ying
    Sheu, Gwo-Tarng
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (09) : 10130 - 10139
  • [42] Induction of accelerated senescence by γ radiation in human solid tumor-derived cell lines expressing wild-type TP53
    Mirzayans, R
    Scott, A
    Cameron, M
    Murray, D
    RADIATION RESEARCH, 2005, 163 (01) : 53 - 62
  • [43] The enrichment of CD8+ T cell in TP53 pathway wild-type microsatellite stable colorectal cancer.
    Cai, Yi
    Zhao, Feilong
    Zhao, Xiaochen
    Bai, Yuezong
    CANCER RESEARCH, 2021, 81 (13)
  • [44] Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
    Moschos, Stergios J.
    Sandhu, Shahneen
    Lewis, Karl D.
    Sullivan, Ryan J.
    Puzanov, Igor
    Johnson, Douglas B.
    Henary, Haby A.
    Wong, Hansen
    Upreti, Vijay V.
    Long, Georgina V.
    Flaherty, Keith T.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1051 - 1065
  • [45] Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
    Stergios J. Moschos
    Shahneen Sandhu
    Karl D. Lewis
    Ryan J. Sullivan
    Igor Puzanov
    Douglas B. Johnson
    Haby A. Henary
    Hansen Wong
    Vijay V. Upreti
    Georgina V. Long
    Keith T. Flaherty
    Investigational New Drugs, 2022, 40 : 1051 - 1065
  • [46] O-phospho-L-tyrosine protects TP53 wild-type cells against ionizing radiation
    Dittmann, KH
    Mayer, C
    Rodemann, HP
    INTERNATIONAL JOURNAL OF CANCER, 2001, 96 : 1 - 6
  • [47] Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
    Rossi, Davide
    Fangazio, Marco
    Rasi, Silvia
    Vaisitti, Tiziana
    Monti, Sara
    Cresta, Stefania
    Chiaretti, Sabina
    Del Giudice, Ilaria
    Fabbri, Giulia
    Bruscaggin, Alessio
    Spina, Valeria
    Deambrogi, Clara
    Marinelli, Marilisa
    Fama, Rosella
    Greco, Mariangela
    Daniele, Giulia
    Forconi, Francesco
    Gattei, Valter
    Bertoni, Francesco
    Deaglio, Silvia
    Pasqualucci, Laura
    Guarini, Anna
    Dalla-Favera, Riccardo
    Foa, Robin
    Gaidano, Gianluca
    BLOOD, 2012, 119 (12) : 2854 - 2862
  • [48] Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts
    Shimada, M
    Kigawa, J
    Kanamori, Y
    Itamochi, H
    Takahashi, M
    Kamazawa, S
    Sato, S
    Terakawa, N
    EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) : 1869 - 1875
  • [49] MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
    Li, Li
    Tan, Yanhong
    Chen, Xiuhua
    Xu, Zhifang
    Yang, Siyao
    Ren, Fanggang
    Guo, Haixiu
    Wang, Xiaojuan
    Chen, Yi
    Li, Guoxia
    Wang, Hongwei
    PLOS ONE, 2014, 9 (11):
  • [50] Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs
    Zhang, Chen
    Martinez-Ledesma, Emmanuel
    Gao, Feng
    Zhang, Wei
    Ding, Jie
    Wu, Shaofang
    Li, Xiaolong
    Wu, Jimin
    Yuan, Ying
    Koul, Dimpy
    Yung, W. K. Alfred
    AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (08): : 1734 - +
12345